Effects of Toona sinensis Leaf Extract and Its Chemical Constituents on Xanthine Oxidase Activity and Serum Uric Acid Levels in Potassium Oxonate-Induced Hyperuricemic Rats
- PMID: 30544886
- PMCID: PMC6321014
- DOI: 10.3390/molecules23123254
Effects of Toona sinensis Leaf Extract and Its Chemical Constituents on Xanthine Oxidase Activity and Serum Uric Acid Levels in Potassium Oxonate-Induced Hyperuricemic Rats
Abstract
Toona sinensis leaf is used as a seasonal vegetable in Korea. A 70% ethanol extract of these leaves exhibited potent xanthine oxidase (XO) inhibition, with a 50% inhibitory concentration (IC50) of 78.4 µM. To investigate the compounds responsible for this effect, bioassay-guided purification led to the isolation of five constituents, identified as quercetin-3-O-rutinoside, quercetin-3-O-β-d-glucopyranoside, 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose (compound 3), quercetin-3-O-α-l-rhamnopyranoside, and kaempferol-3-O-α-l-rhamnopyranoside. Compound 3 showed the most potent inhibition of XO, with an IC50 of 2.8 µM. This was similar to that of allopurinol (IC50 = 2.3 µM), which is used clinically to treat hyperuricemia. Kinetic analyses found that compound 3 was a reversible noncompetitive XO inhibitor. In vivo, the T. sinensis leaf extract (300 mg/kg), or compound 3 (40 mg/kg), significantly decreased serum uric acid levels in rats with potassium oxonate-induced hyperuricemia. Furthermore, ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry analysis identified a high level of compound 3 in the leaf extract. These findings suggest that T. sinensis leaves could be developed to produce nutraceutical preparations.
Keywords: Toona sinensis; hyperuricemia; ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry; uric acid; xanthine oxidase.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




References
-
- Redon P., Maloberti A., Facchetti R., Redon J., Lurbe E., Bombelli M., Mancia G., Grassi G. Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the blood pressure control rate and cardiovascular risk profile study. J. Hypertens. 2018 doi: 10.1097/HJH.0000000000001908. - DOI - PubMed
-
- Maloberti A., Maggioni S., Occhi L., Triglione N., Panzeri F., Nava S., Signorini S., Falbo R., Casati M., Grassi G., Giannattasio C. Sex-related relationships between uric acid and target organ damage in hypertension. J. Clin. Hypertens. (Greenwich). 2018;20:193–200. doi: 10.1111/jch.13136. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources